Ardelyx Announces Proposed Public Offering of Common Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/16/2026
- Wall St set for muted open as tech wobble persists; Tesla gains
- Oil heads for weekly gain with focus on Middle East supply
- Stay risk-off as higher real yields and AI volatility threaten stocks: BofA
- Appleās first foldable iPhone sells out within minutes as preorders begin
- CoreWeave bond rout tests market's math on AI buildout
- Vertiv shares fall on analyst downgrades and options bets
- European stocks rise, dollar set for weekly loss after yields drop
- S&P 500 ends higher as traders shift from AI to healthcare
- Rocket Lab USA (RKLB) Reiterated at Overweight by Cantor Fitzgerald as Neutron Launch Moved to Next Year
- Truist Financial to sell $7.7B LightStream loan portfolio to Carlyle
Ardelyx (ARDX) Prices 7.5M Common Stock Offering at $10/Share
January 8, 2016 6:47 AM ESTArdelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced the pricing of an underwritten public offering of 7,500,000 shares of its common stock at a public offering price of $10.00 per share, before underwriting discounts and commissions, for gross proceeds of $75,000,000. In addition, the Company has granted the underwriters of the offering the right for a period of 30 days to... More



